Cancer is characterized by uncontrolled cellular proliferation that escapes organismal organizational control. The dominant Somatic Mutation Theory attributes malignancy to driver mutations in cell-autonomous oncogenes and tumor suppressors. While genetically supported, SMT faces recognized challenges: cancer-associated mutations are common in normal aging tissues without producing malignancy, and tissue disruption without genetic change can initiate cancer. The CTF framework, integrating the Tissue Organization Field Theory, models cancer as a failure of organismal-level coherence rather than exclusively a cell-autonomous disease. Malignant behavior emerges when cells lose coherence coupling with the tissue organizational field — falling below the C ≥ 0.5 threshold for tissue-level coordination. The cancer cell is not simply a mutated cell — it is a cell that has lost its T field address in the body's organizational architecture and is operating as an autonomous low-coherence system. Therapeutic strategies targeting coherence restoration may complement genetic and pharmacological approaches.
1. The Paradox
Why does a cell that contains the same DNA as every other body cell stop responding to organismal organizational signals and begin growing autonomously? The genetic framework identifies driver mutations but cannot fully explain why the same mutations produce malignancy in disrupted tissue contexts but not in normal ones, or why tissue normalization can suppress malignant behavior in genetically abnormal cells. The organizational question — why does cellular behavior become decoupled from organismal context — remains unanswered.
2. What the Standard Model Got Right
Driver mutations in oncogenes and tumor suppressors are real and causally important. The Hallmarks of Cancer framework correctly identifies the phenotypic features of malignancy. Tissue Organization Field Theory (Soto & Sonnenschein) correctly identifies the role of tissue context in malignant behavior. Bioelectrical normalization of tumor microenvironment suppresses malignancy in animal models. These are the fixed points.
3. Coherence-Loss Model
3.1 Cancer as Sub-Threshold Coherence
The CTF framework treats cancer as a coherence-loss event at the tissue-field level. The cancer cell has fallen below C ≥ 0.5 — the threshold for maintained coherence coupling with the tissue organizational field. Below this threshold, cells revert to default proliferative behavior because they have lost the organizational constraints that maintain differentiated function. The cell is not choosing to proliferate — it has lost the field-level information that tells it not to.
3.2 Tissue-Field Disruption as Primary
The coherence-loss model proposes that tissue-field disruption often precedes and enables genetic instability. When tissue-level organizational coherence is compromised by inflammation, mechanical disruption, chemical carcinogens, or bioelectrical disruption, cells lose the constraints that maintain differentiated state. This releases selection pressure for mutations that enable survival in the disrupted context. Genetic changes are therefore partly consequences of organizational coherence loss, not exclusively causes.
3.3 Metastasis as Coherence Migration
Metastasis is a coherence-migration event. Cells that have lost coherence with their tissue context are no longer constrained to remain in place. They move toward regions where environmental conditions are permissive — where tissue-field organizational coherence is insufficient to suppress their proliferative default. The pre-metastatic niche concept corresponds to remote disruption of tissue-field coherence by circulating factors from the primary tumor.
Testable Predictions
Measurable tissue-field coherence signatures — bioelectrical potential patterns, gap junction connectivity, extracellular matrix organization — should predict cancer development risk before genetic changes are detectable.
Restoration of tissue-field coherence signals in early-stage cancers should suppress malignant behavior even in genetically abnormal cells.
The spatial pattern of cancer progression should correlate with the pattern of tissue-field coherence disruption rather than exclusively with the location of primary mutation accumulation.
Limitations
The quantitative relationship between CTF coherence and measurable tissue-field parameters requires formal specification.
All therapeutic applications require independent clinical validation — no clinical recommendations are made here.
The coherence-loss model does not replace the genetic framework — it proposes a higher-level organizational context.
Conclusion
Cancer is reinterpreted from a cell-autonomous genetic disease to a tissue-level coherence-loss failure. The cell that becomes malignant has not simply accumulated mutations — it has lost integration with the organizational field of its tissue context. Genetic changes and tissue-field disruption are interacting components of a multilevel organizational breakdown. Therapeutic strategies targeting coherence restoration alongside conventional genetic targets may prove more effective than either approach alone.
This paper applies the following move(s) from the master Paradox Resolution Framework. Every paradox in this series resolves by one or more of five structural operations on the incomplete model.
References
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144, 646–674.
Levin, M. (2021). Bioelectric signaling: Reprogrammable circuits underlying embryogenesis, regeneration, and cancer. Cell, 184, 1971–1989.
Soto, A. M., & Sonnenschein, C. (2011). The tissue organization field theory of cancer. Nature Reviews Cancer, 11, 814–822.
Farrior, J. (2026). Coherence Medicine Framework. Christos Energy.
- PR-009: Origin of Life
- PR-011: Aging as Coherence Decay
- PR-012: Placebo Effect
- Vol. II: Coherence Medicine Framework
- PR-023: The Morphogenetic Field
© 2026 Joshua Farrior · Christos™ Energy, Technology & Harmonic Design Consulting, LLC · All Rights Reserved